
06 Sep 2017
LIBERUM: Shield Therapeutics* - US composition patent granted to 2035; further support for long duration of cashflows
This content is only available within our institutional offering.

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
LIBERUM: Shield Therapeutics* - US composition patent granted to 2035; further support for long duration of cashflows
Shield Therapeutics Plc (STX:LON) | 2.8 0 0.0% | Mkt Cap: 29.7m
- Published:
06 Sep 2017 -
Author:
Roger Franklin | Graham Doyle -
Pages:
2 -